Papers/PMID:23167972
Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants.
BMC medicine2012The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
escitalopram — increases antidepressant treatment response rate
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The proportion of responders was significantly greater with citalopram and escitalopram than placebo and the two effect sizes were of similar magnitude.”
Quoted verbatim from Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants.. - Study
- meta-analysis
- Population
- Adults with major depression in placebo-controlled trials of escitalopram (12 trials), eight-week acute treatment, pooled
Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants.2012PMID:23167972Permalink